CHANGING THE WORLD ONE PAINLESS INJECTION AT A TIME
PKA SoftTouch's revenue generation will be largely attributable to the continued growth of the injectable drug market, which is growing at double-digit Compound Annual Growth Rate rates.
The pain-free Micro-Needle addresses the increasing need to self-administer drugs in a painless, safe, cost-effective and easy-to-use manner. This is especially important for an aging population.
The device is extremely cost-effective. The cost of the device is equal to that of the regular syringe with a vial of drug. The painless application will enhance a drug company's penetration into the syringe market.
There are numerous injectable drug markets that can be enhanced by the painless technology and that will sustain PKA for long term growth.
Typically, the PKA Micro-Needle is suitable for injectable drugs such as insulin, heparin, morphine, vaccines, pain medications, wart treatment, TB testing, etc.
PKA SoftTouch, Micro-Needle technology has already been approved to work in earlier clinical trials, with new trials needed for the generation V device. Once all clinical trials are successfully completed, compatibility studies are done, and regulatory approvals obtained, the device will be ready for commercialization. PKA SoftTouch, in collaboration with Mount Sinai Hospital, is developing the protocols for proof of concept clinical trials for insulin used for diabetes control. Mount Sinai in Toronto is widely known in North America and lends high credibility to our technology.
Not only does PKA SoftTouch have its own intellectual property, but it also has access to world-class scientific, medical and technical experts with a track record of innovation.
The PKA SoftTouch patented Micro-Needle will be a market interrupter by changing the way drugs are delivered and administered into the body. This could become a product with strong growth potential.